[ 1 ] Deshaies RJ. Multispecific drugs herald a new era of biopharmaceutical innovation. Nature 2020;580(7803):329‒38. 链接1

[ 2 ] Briukhovetska D, Dorr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021;21(8):481‒99. 链接1

[ 3 ] Conner KP, Devanaboyina SC, Thomas VA, Rock DA. The biodistribution of therapeutic proteins: mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacol Ther 2020;212:107574. 链接1

[ 4 ] Liu LM. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 2018;9(1):15‒32. 链接1

[ 5 ] Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discovery 2019;18(5):358‒78. 链接1

[ 6 ] Chowdhury EA, Meno-Tetang G, Chang HY, Wu S, Huang HW, Jamier T, et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models. Adv Drug Delivery Rev 2021;170:214‒37. 链接1

[ 7 ] Wagner HJ, Weber W, Fussenegger M. Synthetic biology: emerging concepts to design and advance adeno-associated viral vectors for gene therapy. Adv Sci 2021;8(9):2004018. 链接1

[ 8 ] Naldini L. Gene therapy returns to centre stage. Nature 2015;526(7573):351‒60. 链接1

[ 9 ] Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun 2020;11(1):5820. 链接1

[10] Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013;369(24):2313‒23. 链接1

[11] Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015;519(7541):87‒91. 链接1

[12] Le Quellec S, Dane A, Enjolras N, McIntosh J, Rosales C, Negrier C, et al. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins. Haemophilia 2019;25(1):e11‒8. 链接1

[13] Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337(6207):525‒31. 链接1

[14] Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012;119(3):666‒72. 链接1

[15] Le Quellec S, Dane AP, Barbon E, Bordet JC, Mingozzi F, Dargaud Y, et al. Recombinant adeno-associated viral vectors expressing human coagulation FIX-E456H variant in hemophilia B mice. Thromb Haemost 2019;119 (12):1956‒67. 链接1

[16] Wang C, Wu Y, Wang L, Hong B, Jin Y, Hu D, et al. Engineered soluble monomeric IgG1 Fc with significantly decreased non-specific binding. Front Immunol 2017;8:1545. 链接1

[17] Li W, Wu Y, Kong D, Yang H, Wang Y, Shao J, et al. One-domain CD4 fused to human anti-CD16 antibody domain mediates effective killing of HIV-1- infected cells. Sci Rep 2017;7(1). 链接1

[18] Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One 2012;7(11):e49345. 链接1

[19] Challis RC, Ravindra Kumar S, Chan KY, Challis C, Beadle K, Jang MJ, et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc 2019;14(2):379‒414. 链接1

[20] McKeage K. Ravulizumab: first global approval. Drugs 2019;79 (3):347‒52. 链接1

[21] Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies 2020;9(4):64. 链接1

[22] Pincus SH, Craig RB, Weachter L, LaBranche CC, Nabi R, Watt C, et al. Bispecific anti-HIV immunoadhesins that bind Gp120 and Gp41 have broad and potent HIV-neutralizing activity. Vaccines 2021;9(7):774. 链接1

[23] Wu X, Guo J, Niu M, An M, Liu L, Wang H, et al. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. J Clin Invest 2018;128 (6):2239‒51. 链接1

[24] Li S, Qiao Y, Jiang S, Wang B, Kong W, Shan Y. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1. J Controlled Release 2021;338:633‒43. 链接1

[25] Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol 2014;88 (2):1125‒39. 链接1

[26] Ying T, Wang Y, Feng Y, Prabakaran P, Gong R, Wang L, et al. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. mAbs 2015;7(5):922‒30. 链接1

[27] Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 2020;21(4):255‒72. 链接1

[28] Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18(9):599‒612. 链接1

[29] Ogrodnik M, Zhu Yi, Langhi LGP, Tchkonia T, Krüger P, Fielder E, et al. Obesityinduced cellular senescence drives anxiety and impairs neurogenesis. Cell Metab 2019;29(5):1061‒77.e8. 链接1

[30] Campbell MD, Sathish T, Zimmet PZ, Thankappan KR, Oldenburg B, Owens DR, et al. Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype. Nat Rev Endocrinol 2020;16(7):395‒400. 链接1

[31] Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 2016;23(3):427‒40. 链接1

[32] Davidsohn N, Pezone M, Vernet A, Graveline A, Oliver D, Slomovic S, et al. A single combination gene therapy treats multiple age-related diseases. Proc Natl Acad Sci USA 2019;116(47):23505‒11. 链接1

[33] Noh MR, Kong MJ, Han SJ, Kim JI, Park KM. Isocitrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hypertension. Redox Biol 2020;34:101548. 链接1

[34] Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 2018;10(8):emmm.201708791. 链接1

[35] Sponton CH, Kajimura S. AAV-mediated gene therapy as a strategy to fight obesity and metabolic diseases. EMBO Mol Med 2018;10(8):e9431. 链接1

[36] Gaich G, Chien J, Fu H, Glass L, Deeg M, Holland W, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013;18(3):333‒40. 链接1

[37] Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018;9(1):86‒120. 链接1

[38] Nidetz NF, McGee MC, Tse LV, Li C, Cong L, Li Y, et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery. Pharmacol Ther 2020;207:107453. 链接1

[39] Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther 2018;26(12):2717‒26. 链接1

[40] Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest 2021;131(1):e143780. 链接1

[41] Flotte TR. Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther 2020;31(7‒8):398‒9.

[42] Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013;122(1):23‒36. 链接1